A client is prescribed a sympathomimetic eye drop for her glaucoma. The nurse explains that this medication works by causing pupillary ________ which helps ________.

Introduction: Glaucoma is a progressive optic neuropathy characterized by increased intraocular pressure (IOP) that leads to retinal ganglion cell apoptosis. Pharmacological management often utilizes sympathomimetics to enhance aqueous humor drainage through the uveoscleral pathway and reduce production at the ciliary body. A. Miosis is the constriction of the pupil, which is typically associated with cholinergic or parasympathomimetic agents rather than sympathomimetics. While miosis helps open the trabecular meshwork, increasing IOP is a deleterious effect that would exacerbate glaucoma pathology rather than treating the ocular hypertensive state effectively. B. Sympathomimetics, such as apraclonidine or brimonidine, induce MYDRIASIS by stimulating the pupillary dilator muscle via alpha-adrenergic receptors. This physiologic response is coupled with decreased aqueous humor production and increased uveoscleral outflow, which effectively functions to DECREASE IOP, preventing further mechanical damage to the optic nerve head. C. Pupillary constriction, or miosis, is primarily mediated by the parasympathetic nervous system acting on the muscarinic receptors of the iris sphincter. While decreasing IOP is the therapeutic goal for glaucoma, the mechanism of a sympathomimetic agent is specifically directed toward pupillary dilation rather than pupillary constriction. D. Although sympathomimetics correctly cause mydriasis, the second part of this choice is clinically incorrect for a therapeutic intervention. Increasing intraocular pressure would result in optic disc cupping and irreversible visual field loss, which contradicts the entire pharmacological intent of administering anti-glaucoma eye drop medications.